Literature DB >> 33989746

Electric neurostimulation regulates microglial activation via retinoic acid receptor α signaling.

Smadar Goldfarb1, Nina Fainstein1, Tal Ganz2, Dan Vershkov3, Marva Lachish1, Tamir Ben-Hur4.   

Abstract

Brain stimulation by electroconvulsive therapy is effective in neuropsychiatric disorders by unknown mechanisms. Microglial toxicity plays key role in neuropsychiatric, neuroinflammatory and degenerative diseases. We examined the mechanism by which electroconvulsive seizures (ECS) regulates microglial phenotype and response to stimuli. Microglial responses were examined by morphological analysis, Iba1 and cytokine expression. ECS did not affect resting microglial phenotype or morphology but regulated their activation by Lipopolysaccharide stimulation. Microglia were isolated after ECS or sham sessions in naïve mice for transcriptome analysis. RNA sequencing identified 141 differentially expressed genes. ECS modulated multiple immune-associated gene families and attenuated neurotoxicity-associated gene expression. Blood brain barrier was examined by injecting Biocytin-TMR tracer. There was no breakdown of the BBB, nor increase in gene-signature of peripheral monocytes, suggesting that ECS effect is mainly on resident microglia. Unbiased analysis of regulatory sequences identified the induction of microglial retinoic acid receptor α (RARα) gene expression and a putative common RARα-binding motif in multiple ECS-upregulated genes. The effects of AM580, a selective RARα agonist on microglial response to LPS was examined in vitro. AM580 prevented LPS-induced cytokine expression and reactive oxygen species production. Chronic murine experimental autoimmune encephalomyelitis (EAE) was utilized to confirm the role RARα signaling as mediator of ECS-induced transcriptional pathway in regulating microglial toxicity. Continuous intracerebroventricular delivery of AM580 attenuated effectively EAE severity. In conclusion, ECS regulates CNS innate immune system responses by activating microglial retinoic acid receptor α pathway, signifying a novel therapeutic approach for chronic neuroinflammatory, neuropsychiatric and neurodegenerative diseases.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Electroconvulsive seizures (ECS); Electroconvulsive therapy (ECT); Microglia; Neuroinflammation; Neurostimulation; Neurotoxicity; Retinoic acid receptor a (RARa)

Mesh:

Substances:

Year:  2021        PMID: 33989746     DOI: 10.1016/j.bbi.2021.05.007

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  4 in total

Review 1.  Revisiting APP secretases: an overview on the holistic effects of retinoic acid receptor stimulation in APP processing.

Authors:  José J M Vitória; Diogo Trigo; Odete A B da Cruz E Silva
Journal:  Cell Mol Life Sci       Date:  2022-01-28       Impact factor: 9.261

2.  Microglia and their LAG3 checkpoint underlie the antidepressant and neurogenesis-enhancing effects of electroconvulsive stimulation.

Authors:  Neta Rimmerman; Hodaya Verdiger; Hagar Goldenberg; Lior Naggan; Elad Robinson; Ewa Kozela; Sivan Gelb; Ronen Reshef; Karen M Ryan; Lily Ayoun; Ron Refaeli; Einat Ashkenazi; Nofar Schottlender; Laura Ben Hemo-Cohen; Claudia Pienica; Maayan Aharonian; Eyal Dinur; Koby Lazar; Declan M McLoughlin; Ayal Ben Zvi; Raz Yirmiya
Journal:  Mol Psychiatry       Date:  2021-10-14       Impact factor: 15.992

3.  Microbial pathogens induce neurodegeneration in Alzheimer's disease mice: protection by microglial regulation.

Authors:  Tal Ganz; Nina Fainstein; Amit Elad; Marva Lachish; Smadar Goldfarb; Ofira Einstein; Tamir Ben-Hur
Journal:  J Neuroinflammation       Date:  2022-01-06       Impact factor: 8.322

4.  Direct modulation of microglial function by electrical field.

Authors:  Anton Lennikov; Menglu Yang; Karen Chang; Li Pan; Madhu Sudhana Saddala; Cherin Lee; Ajay Ashok; Kin-Sang Cho; Tor Paaske Utheim; Dong Feng Chen
Journal:  Front Cell Dev Biol       Date:  2022-09-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.